Eli Lilly and Company (LLY)
| Market Cap | 1.05T +43.3% |
| Revenue (ttm) | 72.25B +47.4% |
| Net Income | 25.28B +127.6% |
| EPS | 28.15 +129.1% |
| Shares Out | 891.74M |
| PE Ratio | 41.75 |
| Forward PE | 32.70 |
| Dividend | $6.92 (0.59%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 2,092,002 |
| Open | 1,143.00 |
| Previous Close | 1,146.90 |
| Day's Range | 1,139.00 - 1,177.58 |
| 52-Week Range | 623.78 - 1,249.45 |
| Beta | 0.51 |
| Analysts | Buy |
| Price Target | 1,270.37 (+8.08%) |
| Earnings Date | Aug 5, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for LLY stock is "Buy." The 12-month stock price target is $1,270.37, which is an increase of 8.08% from the latest price.
News
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.
Lilly tells Bloomberg ads ‘truthful,’ will defend against Novo suit ‘vigorously’
A spokesperson for Eli Lilly (LLY) told Bloomberg that the company’s weight loss drug ads are “truthful” and “transparent,” adding that the company will defend itself “vigorously” against the lawsuit…
Novo Sues Rival Lilly Over Weight-Loss Ads
Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo'...
Eli Lilly (LLY) Hit with Lawsuit by Rival Novo Nordisk Over Weight-Loss Drug Ads
Competition between the drug makers is intensifying.
Cramer's Mad Dash: Eli Lilly
CNBC's Jim Cramer delivers his daily Mad Dash.
Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising
Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly misleading ...
Novo Nordisk sues Eli Lilly over weight-loss drug advertising claims
Novo Nordisk has filed a lawsuit against Eli Lilly (LLY) in a US federal court, accusing its rival of running false and misleading advertising campaigns for its blockbuster diabetes and weight-loss dr...
Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
The drugmaker says Lilly isn't including the most up-to-date clinical information about its drugs
Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugs
The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.
Novo Nordisk files lawsuit against ‘misleading’ GLP-1 ads from Eli Lilly
Novo Nordisk (NVO) announced that it has filed a lawsuit against Eli Lilly (LLY) in the United States District Court for the District of New Jersey for what it calls…
Novo Nordisk suing Eli Lilly over weight-loss ads, Bloomberg reports
Novo Nordisk (NVO) said in U.S. federal court that it is suing Eli Lilly (LLY), claiming that its competitor’s advertising for its obesity shot Zepbound and diabetes injection Mounjaro is…
Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising
Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo's drugs.
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior efficacy r...
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Thursday's announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma's increasing embrace of a long-stigmatized cla...
One in Every Five U.S. Homes Using GLP-1s: What it Means for Consumer Trends
MichaelAaron Flicker examines the growing impact of GLP-1 medications on consumer behavior, noting that roughly one in five American households has someone using a GLP-1 drug. He explains how that tre...
Abivax re-engages Centerview amid renewed takeover interest, La Lettre says
Marc de Garidel’s company suspended takeover talks with pharma giants including AstraZeneca (AZN) and Eli Lilly (LLY) last month as it secured an EUR 800M capital raise. Its new funding…
Looking to diversify away from AI trade? Buy these 3 stocks
For investors seeking to pare exposure to the artificial intelligence (AI) trade amid boom-induced volatility, shifting capital toward overlooked equities offers a compelling strategic alternative. Ma...
Helus Pharma price target lowered to $45 from $48 at Guggenheim
Guggenheim lowered the firm’s price target on Helus Pharma (HELP) to $45 from $48 and keeps a Buy rating on the shares. The Eli Lilly (LLY) transaction for AtaiBeckley (ATAI)…
AtaiBeckley stock is soaring, and it has Eli Lilly to thank
AtaiBeckley (ATAI) shares are ripping higher on Thursday morning after pharmaceutical giant Eli Lilly (LLY) said it will acquire the clinical-stage biotechnology firm for up to $3.8 billion. Lilly has...
Why Is AtaiBeckley N.V. (ATAI) Stock Up Today?
AtaiBeckley N.V. ($ATAI) stock surged on Thursday after the clinical-stage biopharmaceutical company announced an acquisition agreement with global pharmaceutical firm Eli Lilly ($LLY). Under the term...
Lilly Buys Psychedelic Drugmaker AtaiBeckley for $3.8 Billion
Eli Lilly & Co. agreed to buy AtaiBeckley Inc. for as much as $3.8 billion, underscoring growing interest from large drugmakers in psychedelic medicine. Madison Muller has more on "Bloomberg Open Inte...
Eli Lilly (LLY) Buys Psychedelic Drug Maker AtaiBeckley for $2.8 Billion
The pharma giant has a history of treating mental health conditions.
Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion
Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker's recent buying spree.
Eli Lilly to acquire AtaiBeckley for $6.75 per share plus $2.50 per share CVR
Eli Lilly (LLY) announced a definitive agreement for Lilly to acquire AtaiBeckley (ATAI). AtaiBeckley is advancing a pipeline of rapid-acting neuroplastogens, including multiple clinical-stage program...